OMNI MEDICAL HOLDINGS INC Form 10QSB February 14, 2006

> U. S. Securities and Exchange Commission Washington, D. C. 20549

> > FORM 10-QSB

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2005

[] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 000-26177

OMNI MEDICAL HOLDINGS, INC.

(Name of Small Business Issuer in its Charter)

UTAH

87-0425275

(I.R.S. Employer I.D. No.)

(State or Other Jurisdiction of incorporation or organization)

1257 Lake Plaza Drive, Suite 219 Colorado Springs, Colorado 80906 ______(Address of Principal Executive Offices)

Registrant's Telephone Number: (719) 884-2131

N/A

(Former name, former address and former fiscal year, if changed since last report)

Check whether the Registrant (1) filed all reports required to be filed by Sections 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

(1) Yes X No (2) Yes X No

Indicate by check mark whether the Registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act) Yes $$\rm No\ X$$

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Not applicable.

APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:

December 31, 2005 - 12,912,069 shares

Transitional small business disclosure format (check one): Yes X No

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

The Financial Statements of the Registrant required to be filed with this 10-QSB Quarterly Report were prepared by management, and commence on the following page, together with Related Notes. In the opinion of management, the Financial Statements fairly present the financial condition of the Registrant.

Omni Medical Holdings, Inc.

Condensed Consolidated Financial Statements

December 31, 2005

Omni Medical Holdings, Inc. Unaudited Condensed Consolidated Balance Sheet December 31, 2005

ASSETS

\$ 2,081,265 113,453 5,317 86,914
2,286,949
1,370,526
25,000
3,456,945
1,904,647
5,386,592
\$ 9,044,067

See notes to condensed consolidated financial statements $${\rm F}{\rm -2}$$

Omni Medical Holdings, Inc.

Unaudited Condensed Consolidated Balance Sheet [continued] December 31, 2005

LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:	
Accounts payable	\$ 838,625
Bank overdraft	10,128
Accrued expenses	2,744,997
Line of credit	117,283
Current portion notes payable	2,921,074
Total current liabilities	6,632,107
Convertible debt	1,830,672
Senior note payable-Note 6	133 , 333
Derivative liability on warrants-Note 6	240,000
Notes payable	2,061,277
Current portion notes payable	(2,921,074)
Total long-term liabilities	1,344,208
Total liabilities	7,976,315
Minority interest	(246,310)
Stockholders' equity-Note 5:	
Preferred stock, no par value, 1,000,000 shares authori	zed,
no shares issued and outstanding	-
Common stock, par value \$0.001 per share; 50,000,000	
shares authorized; 12,912,069 issued and outstanding	12,912
Common stock to be issued under reorganization agreemen	
118,665 shares	119 6,218,983
Capital in excess of par value Unrealized loss on investment	(165,520)
Accumulated deficit	(4,752,432)
Accumulated delicit	(4,752,452)
Total stockholders' equity	1,314,062
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 9,044,067

See notes to condensed consolidated financial statements $$\rm F{-}3$$

Omni Medical Holdings, Inc. Unaudited Condensed Consolidated Statements of Operations For the three and nine month periods ended December 31, 2005 and 2004

	For the thr	ee months ended	d For the nine	months ended	
	Dec	ember 31,	December 31,		
	2005	2004	2005	2004	
Revenue	\$1,251,743	\$ 238,518	\$ 4,233,046	\$ 722 , 093	
Cost of sales	740,567	169,180	2,285,136	431,291	
Gross operating profit General and administrati	511,176 ve	69,338	1,947,910	290,802	
expenses	1,114,906	178,375	3,156,581	554,622	
Income (loss) from operations	(603,730)	(109,037)	(1,208,671)	(263,820)	

Other income (expense):

Interest expense Loss on sale of assets		(10,461)	(571,982)	(28,118)
Gain (loss) on derivatives instrument	s 60,000		60,000	
Realized loss on investment	-	(77,582)	_	(77,582)
Total other income (expense)		(88,043)	(511,982)	(105,700)
Loss from continuing operations before minority interest Minority interest	(825,421) 45,266	(197,080)	(1,720,653) 96,067	(369,520)
Loss from continuing operations before income taxes Provision for income taxe		(197,080)	(1,624,586)	(369,520)
Loss from continuing operations	(780,155)	(197,080)	(1,624,586)	(369,520)
Discontinued operations: Loss from discontinued operations, net of tax Loss on disposal of discontinued operations,	_	(52,322)		(150,629)
net of tax	-	-	(6,520)	-
Net loss from discontinue operations	d _	(52,322)	(100,753)	(150,629)
Net loss		\$ (249,402)		\$ (520,149)
Other comprehensive incom				
Unrealized gain (loss) on investments		(161,327)	(27,092)	(161,327)
Total comprehensive incom (loss)		\$ (410,729)	\$(1,752,431)	\$ (681,476)
Loss per share basic and Continuing operations	diluted: \$ (0.06)	\$ (0.04)	\$ (0.13)	\$ (0.08)
Discontinued operations	======== \$ 0.00	\$ (0.01)	\$ (0.01)	======================================
Net loss per share-basic and diluted	\$ (0.06)	\$ (0.05)	======================================	\$ (0.11)
Weighted average number o common shares outstanding -basic and diluted	f 12,901,089	5,502,984	12,613,559	4,777,142

See notes to condensed consolidated financial statements $$\rm F{-}4$$

Omni Medical Holdings, Inc.

Unaudited Consolidated Statements of Cash Flows For the nine month periods ended December 31, 2005 and 2004 $\,$

CASE FLOWS FROM OPERATING ACTIVITIES Net loss (520,149) Adjustments to reconcile net loss to net cash used in continuing operations: Depreciation and amortization State of the services Stock issued for services Stock issued f		2005	2004
Adjustments to reconcile net loss to net cash used in continuing operations: Depreciation and amortization 548,434 151,752 Stock-based compensation expense - 7,342 Stock issued for services - 667,725 Non-cash interest on senior notes payable 133,333 - Gain on derivative instruments (96,067) - Loss on disposal of discontinued operations 6,520 Loss on sale of assets - 21,878 Realized loss on investment - 77,582 Changes in operating assets and liabilities, net of effect of business acquisition and disposition: Accounts receivable (385,475) (21,395) Prepaid expenses (9,588) 2,568 Deposits 7,763 (350) Accounts payable 501,294 7,665 Bank overdraft 10,128 - Accrued expenses 910,121 3,432 Net cash used in operating activities (158,876) (201,930) CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (146,840) (1,114) Proceeds from sale of assets - 1,021 Software development (240,377) - Proceeds from sale of investments - 107,219 Net cash provided by (used in) investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit (46,170) 26,650 Proceeds from sale of assets - 1,021 Software development (240,377) - Proceeds from sale of common stock 151,000 16,350 Net cash provided by (used in) investing activities 531,244 105,084 Met cash provided by financing activities 531,244 105,084 Met CINCREASE (DECREASE) IN CASH (14,849) 10,220 CASH AT BEGINNING OF FERIOD 14,849 6,140		(1 725 330)	\$ (520 149)
cash used in continuing operations:Depreciation and amortization548,434151,752Stock-based compensation expense-7,342Stock issued for services-67,725Non-cash interest on senior notes payable133,333-Gain on derivative instruments(60,000)-Minority interest(96,067)-Loss on disposal of discontinuedoperations6,520Loss on sale of assets-21,878Realized loss on investment-77,582Changes in operating assets and-77,63liabilities, net of effect of businessacquisition and disposition:Accounts receivable(385,475)Accounts receivable(385,475)(21,395)Accounts payable501,294Deposits7,763(350)Accounts payable501,2947,685Bank overdraft10,128Accrued expenses910,1213,432Net cash used in operating activities(146,840)(1,114)Proceeds from sale of assets-107,219-Froceeds from sale of investments-107,219Net cash provided by (used in) investing activities(387,217)107,126CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit(46,170)26,650Proceeds from the issuance of common stock151,00016,350Net cash provided by financing activitie		(1,723,333)	Υ (JZU, 149)
Stock-based compensation expense-7,342Stock issued for services-67,725Non-cash interest on senior notes payable133,333-Gain on derivative instruments(60,000)-Minority interest(96,067)-Loss on disposal of discontinuedoperations6,520Loss on sale of assets-21,878Realized loss on investment-77,582Changes in operating assets and11abilities, net of effect of business2,568Deposits7,763(350)Accounts receivable(385,475)(21,395)Prepaid expenses(9,588)2,558Deposits7,763(350)Accounts payable501,2947,685Bank overdraft10,128-Accrued expenses910,1213,432Net cash used in operating activities(146,840)(1,114)Proceeds from sale of assets-107,219Net cash provided by (used in) investing activitiesNet cash provided by (used in) investing activitiesNet cash provided by (used in) investing activitiesProceeds from issuance of common stock151,00016,350Proceeds from the issuance of common stock151,00016,350Proceeds from	-		
Stock-based compensation expense-7,342Stock issued for services-67,725Non-cash interest on senior notes payable133,333-Gain on derivative instruments(60,000)-Minority interest(96,067)-Loss on disposal of discontinuedoperations6,520Loss on sale of assets-21,878Realized loss on investment-77,582Changes in operating assets and11abilities, net of effect of business2,568Deposits7,763(350)Accounts receivable(385,475)(21,395)Prepaid expenses(9,588)2,558Deposits7,763(350)Accounts payable501,2947,685Bank overdraft10,128-Accrued expenses910,1213,432Net cash used in operating activities(146,840)(1,114)Proceeds from sale of assets-107,219Net cash provided by (used in) investing activitiesNet cash provided by (used in) investing activitiesNet cash provided by (used in) investing activitiesProceeds from issuance of common stock151,00016,350Proceeds from the issuance of common stock151,00016,350Proceeds from			
Stock issued for services-67,725Non-cash interest on senior notes payable 133,333-Gain on derivative instruments(60,000)Minority interest(96,067)Loss on disposal of discontinuedoperations6,520Loss on sale of assets-Realized loss on investment-77,582Changes in operating assets andliabilities, net of effect of businessacquisition and disposition:Accounts receivable(385,475)Accounts receivable(9,588)2,568Deposits7,763Accounts payable501,294Shak overdraft10,128Accrued expenses910,121Accrued expenses(158,876)Purchase of property and equipment(146,840)Proceeds from sale of assets-107,219107,226CASH FLOWS FROM INVESTING ACTIVITIESPurchase of property and equipment(146,840)Proceeds from sale of investmentsNet cash provided by (used in)investing activities(387,217)Net cash provided by (used in)investing activities(31,124Proceeds from sale of credit(46,170)26,650Proceeds from subance of debt651,145Activities531,244Net cash provided by financingactivities531,244Net cash provided by financingactivities531,244Net cash provided by financingActivities <td></td> <td>548,434</td> <td></td>		548,434	
Non-cash interest on senior notes payable133,333-Gain on derivative instruments(60,000)-Minority interest(96,067)-Loss on disposal of discontinuedoperations6,520Loss on sale of assets-21,878Realized loss on investment-77,582Changes in operating assets and-77,582Liabilities, net of effect of businessacquisition and disposition:-Accounts receivable(385,475)(21,395)Prepaid expenses(9,588)2,568Deposits7,763(350)Accounts payable501,2947,665Bank overdraft10,128-Accrued expenses910,1213,432Net cash used in operating activities(146,840)(1,114)Proceeds from sale of investments-107,219Net cash provided by (used in) investing activities-107,219Net cash provided by (used in) investing activities(387,217)107,126CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit(46,170) (16,14526,650Proceeds from issuance of debt651,14578,000Net cash provided by financing activitiesNet cash provided by financing ac		-	
Gain on derivative instruments(60,000)-Minority interest(96,067)-Loss on disposal of discontinuedoperations6,520Loss on sale of assets-21,878Realized loss on investment-77,582Changes in operating assets and1-liabilities, net of effect of businessacquisition and disposition:-Accounts receivable(385,475)(21,395)Prepaid expenses(9,588)2,558Deposits7,763(350)Accounts payable501,2947,685Bank overdraft10,128-Accrued expenses910,1213,432Net cash used in operating activities(158,876)(201,930)CASH FLOWS FROM INVESTING ACTIVITIES-1,021Purchase of property and equipment(146,840)(1,114)Proceeds from sale of assets-1,021Software development(240,377)-Proceeds from sale of investmentsNet cash provided by (used in) investing activities(387,217)107,126CASH FLOWS FROM FINANCING ACTIVITIESBorrowings on line of credit(46,170)26,650Proceeds from the issuance of common stockNet cash provided by financing activitiesNet cash provided by financing activitiesNet cash provided by financing activitiesNet cash provided by financing activities <td></td> <td></td> <td>67,725</td>			67,725
Minority interest(96,067)-Loss on disposal of discontinued operations6,520Loss on sale of assets-Realized loss on investment-77,582Changes in operating assets and liabilities, net of effect of business acquisition and disposition: Accounts receivable(385,475)Accounts receivable(385,475)(21,395)Prepaid expenses(9,588)2,568Deposits7,763Accounts payable501,294Shak overdraft10,128Accrued expenses910,121Accrued expenses(158,876)Purchase of property and equipment(146,840)Proceeds from sale of assets-107,219-Proceeds from sale of investments-Net cash provided by (used in) investing activities(387,217)Net cash provided by (used in) investing activities(387,217)Net cash provided by (lasd in) investing activities(146,170)Proceeds from issuance of common stock151,000Net payments of notes payable(224,731)Proceeds from the issuance of common stock151,000Proceeds from the issuance of common stock151,000Net cash provided by financing activities-Net cash provided by financing activities-Net cash provided by financing activities-Net cash provided by financing activities-Net ash provided by financing activities-Net ash provided by financing activities <td< td=""><td></td><td></td><td>_</td></td<>			_
Loss on disposal of discontinued operations 6,520 Loss on sale of assets - 21,878 Realized loss on investment - 77,582 Changes in operating assets and liabilities, net of effect of business acquisition and disposition: Accounts receivable (385,475) (21,395) Prepaid expenses (9,588) 2,568 Deposits 7,763 (350) Accounts payable 501,294 7,685 Bank overdraft 10,128 - Accrued expenses 910,121 3,432 Net cash used in operating activities (158,876) (201,930) CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (146,840) (1,114) Proceeds from sale of assets - 1,021 Software development (240,377) - Proceeds from sale of investments - 107,219 Net cash provided by (used in) investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit (46,170) 26,650 Proceeds from fisuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 CASH AT BEGINNING OF PERIOD \$ 0 \$ 16,420			_
Loss on sale of assets - 21,878 Realized loss on investment - 77,582 Changes in operating assets and liabilities, net of effect of business acquisition and disposition: - 77,582 Accounts receivable (385,475) (21,395) Prepaid expenses (9,588) 2,568 Deposits 7,763 (350) Accounts payable 501,294 7,665 Bank overdraft 10,128 - Accrued expenses 910,121 3,432 Outcase of property and equipment (146,840) (1,114) Proceeds from sale of assets - 1,021 Software development (240,377) - Proceeds from sale of investments - 107,219 Net cash provided by (used in) investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES Eorrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 16,550 Proceeds from the issuance of common stock 151,000 16,550 <t< td=""><td></td><td>()</td><td></td></t<>		()	
Realized loss on investment - 77,582 Changes in operating assets and liabilities, net of effect of business acquisition and disposition: - 77,582 Accounts receivable (385,475) (21,395) Prepaid expenses (9,588) 2,568 Deposits 7,763 (350) Accounts payable 501,294 7,685 Bank overdraft 10,128 - Accrued expenses 910,121 3,432 Accrued expenses 910,121 3,432 Purchase of property and equipment (146,840) (1,114) Proceeds from sale of assets - 10,21 Software development (240,377) - Net cash provided by (used in) - - investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES - - Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net cash provided by financing - - Activities 531,244 105,084 Operating - -	operations	6,520	
Changes in operating assets and liabilities, net of effect of business acquisition and disposition: Accounts receivable (385,475) (21,395) Prepaid expenses (9,588) 2,568 Deposits 7,763 (350) Accounts payable 501,294 7,685 Bank overdraft 10,128 - Accrued expenses 910,121 3,432 	Loss on sale of assets	-	
liabilities, net of effect of business acquisition and disposition: Accounts receivable (385,475) (21,395) Prepaid expenses (9,588) 2,568 Deposits 7,763 (350) Accounts payable 501,294 7,685 Bank overdraft 10,128 - Accrued expenses 910,121 3,432 Net cash used in operating activities (158,876) (201,930) CASH FLOWS FROM INVESTING ACTIVITIES - - Purchase of property and equipment (146,840) (1,114) Proceeds from sale of investments - 107,219 Software development (240,377) - Net cash provided by (used in) investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES - - - Net cash provided by (used in) investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES - - - Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916)		-	77,582
acquisition and disposition: Accounts receivable (385,475) (21,395) Prepaid expenses (9,588) 2,568 Deposits 7,763 (350) Accounts payable 501,294 7,685 Bank overdraft 10,128 - Accrued expenses 910,121 3,432 Accrued expenses 910,121 3,432 Met cash used in operating activities (158,876) (201,930) CASH FLOWS FROM INVESTING ACTIVITIES - - Purchase of property and equipment (146,840) (1,114) Proceeds from sale of assets - 1,021 Software development (240,377) - Net cash provided by (used in) investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 16,350 Proceeds from the issuance of common stock 151,000 16,350 Proceeds from the issuance of common stock 151,000 16,350 Order from the issuance of common stock 151,000 16,350 <td></td> <td></td> <td></td>			
Accounts receivable (385,475) (21,395) Prepaid expenses (9,588) 2,568 Deposits 7,763 (350) Accounts payable 501,294 7,685 Bank overdraft 10,128 - Accrued expenses 910,121 3,432 Net cash used in operating activities (158,876) (201,930) CASH FLOWS FROM INVESTING ACTIVITIES - - Purchase of property and equipment (146,840) (1,114) Proceeds from sale of assets - 1,021 Software development (240,377) - Net cash provided by (used in) investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES - - Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) 10,280			
Prepaid expenses (9,588) 2,568 Deposits 7,763 (350) Accounts payable 501,294 7,685 Bank overdraft 10,128 - Accrued expenses 910,121 3,432 Accrued expenses 910,121 3,432 Net cash used in operating activities (158,876) (201,930) CASH FLOWS FROM INVESTING ACTIVITIES - - Purchase of property and equipment (146,840) (1,114) Proceeds from sale of assets - 1,021 Software development (240,377) - Net cash provided by (used in) investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES - - Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Met cash provided by financing activities 531,244 105,084 NET I		(385 475)	(21 395)
Deposits 7,763 (350) Accounts payable 501,294 7,685 Bank overdraft 10,128 - Accrued expenses 910,121 3,432 Net cash used in operating activities (158,876) (201,930) CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (146,840) (1,114) Proceeds from sale of assets - 1,021 Software development (240,377) - Proceeds from sale of investments - 107,219 Net cash provided by (used in) investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 Net cash provided by financing activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH 14,849 6,140 <t< td=""><td></td><td></td><td></td></t<>			
Accounts payable 501,294 7,685 Bank overdraft 10,128 - Accrued expenses 910,121 3,432 Accrued expenses 910,121 3,432 Net cash used in operating activities (158,876) (201,930) CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (146,840) (1,114) Proceeds from sale of assets - 107,219 Software development (240,377) - Net cash provided by (used in) investing activities - 107,219 Net cash provided by (used in) investing activities - 107,126 CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 Net cash provided by financing activities			
Accrued expenses910,1213,432Net cash used in operating activities(158,876)(201,930)CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment(146,840)(1,114)Proceeds from sale of assets-1,021Software development(240,377)-Proceeds from sale of investments-107,219Net cash provided by (used in) investing activitiesNet cash provided by (used in) investing activities(387,217)107,126CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit(46,170) (26,65026,650Proceeds from issuance of debt651,145 (15,916)78,000Net cash provided by financing activities531,244 (15,916)105,084Proceeds from the issuance of common stock151,000 (16,350			
Net cash used in operating activities(158,876)(201,930)CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Proceeds from sale of assets1,021Software development(240,377)Proceeds from sale of investments-Net cash provided by (used in) investing activities-Net cash provided by (used in) investing activities107,126CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit(46,170)Proceeds from issuance of debt651,145Proceeds from the issuance of common stock151,000Net cash provided by financing activities	Bank overdraft	10,128	-
activities (158,876) (201,930) CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (146,840) (1,114) Proceeds from sale of assets - 1,021 Software development (240,377) - Proceeds from sale of investments - 107,219 Net cash provided by (used in) - - investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES - - Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) 10,280 CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$ 0 \$	Accrued expenses	910,121	3,432
activities (158,876) (201,930) CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (146,840) (1,114) Proceeds from sale of assets - 1,021 Software development (240,377) - Proceeds from sale of investments - 107,219 Net cash provided by (used in) - - investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES - - Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) 10,280 CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$ 0 \$			
CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (146,840) (1,114) Proceeds from sale of assets - 1,021 Software development (240,377) - Proceeds from sale of investments - 107,219 Net cash provided by (used in) investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) 10,280 CASH AT BEGINNING OF PERIOD \$ 0 \$ 16,420		(150 076)	(201 020)
Purchase of property and equipment(146,840)(1,114)Proceeds from sale of assets-1,021Software development(240,377)-Proceeds from sale of investments-107,219Net cash provided by (used in) investing activities(387,217)107,126CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit(46,170)26,650Proceeds from issuance of debt651,14578,000Net payments of notes payable(224,731)(15,916)Proceeds from the issuance of common stock151,00016,350Net cash provided by financing activities531,244105,084NET INCREASE (DECREASE) IN CASH(14,849)10,280CASH AT BEGINNING OF PERIOD\$0\$16,420	activities	(130,070)	(201,930)
Proceeds from sale of assets-1,021Software development(240,377)-Proceeds from sale of investments-107,219Net cash provided by (used in) investing activitiesNet cash provided by (used in) investing activitiesCASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit(46,170) (46,170)26,650Proceeds from issuance of debt651,145 (15,916)78,000Net payments of notes payable(224,731) (15,916)16,350Proceeds from the issuance of common stock151,000 (16,35016,350Net cash provided by financing activities531,244 (14,849)105,084NET INCREASE (DECREASE) IN CASH (14,849)10,28010,280CASH AT BEGINNING OF PERIOD\$0\$16,420	CASH FLOWS FROM INVESTING ACTIVITIES		
Software development(240,377)-Proceeds from sale of investments-107,219Net cash provided by (used in) investing activities(387,217)107,126CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit(46,170) (46,170)26,650Proceeds from issuance of debt651,145 (15,916)78,000Net payments of notes payable(224,731) (15,916)(15,916)Proceeds from the issuance of common stock151,000 (16,35016,350Net cash provided by financing activities531,244 (14,849)105,084NET INCREASE (DECREASE) IN CASH (14,849)10,280 (14,849)CASH AT BEGINNING OF PERIOD\$0\$16,420		(146,840)	(1,114)
Proceeds from sale of investments-107,219Net cash provided by (used in) investing activities107,126CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit(46,170) (46,170)26,650Proceeds from issuance of debt651,145 (15,916)78,000Net payments of notes payable(224,731) (15,916)16,350Proceeds from the issuance of common stock151,000 (16,35016,350Net cash provided by financing activities531,244 (14,849)105,084 (10,280NET INCREASE (DECREASE) IN CASH (14,849)(14,849) (10,28010,280 (140CASH AT END OF PERIOD\$0\$		-	1,021
Net cash provided by (used in) investing activities		(240,377)	-
investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) 10,280 CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$	Proceeds from sale of investments	_	107,219
investing activities (387,217) 107,126 CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) 10,280 CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$	 Net cash provided by (used in)		
CASH FLOWS FROM FINANCING ACTIVITIES Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) 10,280 CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$		(387,217)	107,126
Borrowings on line of credit (46,170) 26,650 Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$ 0 \$ 16,420	5		,
Proceeds from issuance of debt 651,145 78,000 Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$ 0 \$	CASH FLOWS FROM FINANCING ACTIVITIES		
Net payments of notes payable (224,731) (15,916) Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing Net cash provided by financing 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) 10,280 CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$ 0 \$			
Proceeds from the issuance of common stock 151,000 16,350 Net cash provided by financing activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) 10,280 CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$ 0 \$			
Net cash provided by financing activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) 10,280 CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$ 0 \$ 16,420			
activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) 10,280 CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$ 0 \$ 16,420	Proceeds from the issuance of common stock	151,000	16,350
activities 531,244 105,084 NET INCREASE (DECREASE) IN CASH (14,849) 10,280 CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$ 0 \$ 16,420	Net cash provided by financing		
CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$ 0 \$	· · · ·	531,244	105,084
CASH AT BEGINNING OF PERIOD 14,849 6,140 CASH AT END OF PERIOD \$ 0 \$			
CASH AT END OF PERIOD \$ 0 \$ 16,420			
	CASH AT BEGINNING OF PERIOD	14,849	6,140
	CASH AT END OF PERIOD \$	0	\$ 16.420
	=		

See accompanying notes to financial statements $$\rm F{-}5$$

Omni Medical Holdings, Inc. Consolidated Statements of Cash Flows [continued] For the nine month periods ended December 31, 2005 and 2004

		2005	2004	
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for interest in continuing operations Cash paid for interest in discontinued operations Cash paid for income taxes	Ş	140,689 _ _	\$ 23 ,	818 _ _
NON-CASH OPERATING ACTIVITIES: Stock issued as prepaid expenses	\$	_	\$ 72 ,	379
NON-CASH INVESTING ACTIVITIES: Stock issued for short-term investments	\$	_	\$507 ,	454
NON-CASH FINANCING ACTIVITIES: Stock issued to relinquish debt	Ş	25,696	\$137 ,	500
BUSINESS ACQUISITIONS: Fair value of assets acquired Issuance of debt/assumption of liabilities Common stock issued at acquisition		,357,006 (357,006) ,000,000)	Ş	
Cash paid	\$ ===	0	\$ =====	0

See accompanying notes to financial statements $$\rm F{-}6$$

Omni Medical Holdings, Inc. Notes to Condensed Consolidated Financial Statements December 31, 2005

Note 1 BUSINESS, ORGANIZATION AND INTERIM FINANCIAL STATEMENTS

Business - Omni Medical Holdings, Inc. ("Omni"), a Utah corporation, provides medical billing and transcription services, and electronic medical record solutions to medical practitioners.

Interim financial statements-The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10QSB and Item 310 (b) of Regulation S-B. Accordingly, they do not include all of the information and footnotes required by accounting principles for complete financial statements generally accepted in the United States of America. In the opinion of management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company's financial position as of December 31, 2005. There has not been any change in the significant accounting policies of Omni Medical Holdings, Inc. for the periods presented. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 2005.

Note 2 BUSINESS ACQUISITIONS

Effective April 15, 2005, the Company entered into an Stock Purchase Agreement ("the Plum Creek agreement") whereby the Company acquired 100% of the outstanding shares of Plum Creek Outpatient, Inc., ("Plum Creek") an Illinois corporation and provider of medical supplies in exchange for 1,000,000 pre-split shares (250,000 post-split shares) of the Company's common stock that are "restricted securities" as defined in Rule 144 of the Securities and Exchange Commission. The Plum Creek agreement calls for a Revenue Bonus to be paid to the sellers based on annual calculations of the combined revenue of the Company and its affiliates relating to medical supplies during two revenue bonus periods ending April 15, 2006 and 2007. The Company also entered into a Put Option agreement whereby anytime during the two year period from the date of acquisition the Company, at the request of the seller, may be required to purchase some or all of the 1,000,000 issued shares at a price of \$0.20 per share or issue additional shares of the Company's common stock equal in number to the shortfall in payment of the Put Price plus ten percent divided by the closing price per share at the close of business on the last day of the payment period.

The following table summarizes the estimated fair values of the Plum Creek assets acquired and liabilities assumed as of April 15, 2005, the date of acquisition:

Accounts receivable, net	\$426 , 960
Equipment	40,000
Accounts payable	(5,000)
Accrued expenses	(261,960)
Net assets acquired	\$ 200,000

F - 7

Omni Medical Holdings, Inc. Notes to Consolidated Financial Statements December 31, 2005

Note 2 BUSINESS ACQUISITIONS-[continued]

On April 15, 2005 the Company also entered into an Asset Purchase Agreement ("the Stat agreement") whereby the Company acquired the assets of Stat Anesthesia, P.C., ("Stat") an Illinois corporation and medical provider, in exchange for 4,000,000 pre-split shares(1,000,000 postsplit shares) of the Company's common stock that were also "restricted securities" as defined in Rule 144 of the Securities and Exchange Commission. Additionally, Stat signed an Administrative Services Agreement with the Company in which the Company will provide financial and administrative services for all of Stat's operations. While the Company will have complete control over the administrative and financial affairs of Stat, the Company will not be involved in any way in the practice of medicine. The Stat agreement also calls for a Revenue Bonus to be paid to the sellers based on annual calculations of the combined revenue of the Company and its affiliates relating to medical services during two revenue bonus periods ending April 15, 2006 and 2007. The Company also entered into a Put Option agreement whereby anytime during the two year period from the date of acquisition the Company, at the request of the seller, may be required to purchase some or all of the 4,000,000 issued shares at a price of \$0.20 per share or issue additional shares of the Company's common stock equal in number to the

shortfall in payment of the Put Price plus ten percent divided by the closing price per share at the close of business on the last day of the payment period.

The following table summarizes the estimated fair values of the Stat assets acquired and liabilities assumed as of April 15, 2005, the date of acquisition:

Accounts receivable,	net	\$850,046
Equipment		40,000
Accrued expenses		(90,046)
Net assets acquired		\$800,000

The DataFuzion, Plum Creek and Stat acquisitions were accounted for as purchases and their results of operations are included in the Company's financial statements from the date of acquisition.

The following proforma financial information presents results as if the DataFuzion Plum Creek and Stat acquisitions had occurred at the beginning of the nine month periods ended December 31, 2005 and 2004:

2005

2004

Revenues Net loss	 366,042 579,562)	 735,116 432,428)
Basic and diluted loss		
per share	\$ (0.13)	\$ (0.09)

F-8

Omni Medical Holdings, Inc. Notes to Condensed Consolidated Financial Statements December 31, 2005

Note 3 GOING CONCERN

The Company's financial statements for the periods ended December 31, 2005 and 2004 show incurred net losses of \$1,725,339 and \$520,149, respectively, and has a working capital deficiency of \$4,340,158, as of December 31, 2005, raising substantial doubt about the company's ability to continue as a going concern. Management's plans to address concerns raised by this issue include:

a. Through the acquisition of Plum Creek Outpatient and administrative services agreement with Stat Anesthesia, P.C., the Company believes it has already acquired significant asset and adequate liquid assets for operation. Furthermore, management believes these companies will provide significant cash flow to provide for all corporate needs.

b. The Company also plans to raise additional capital and is working with a number of financial sources to achieve this.

There is no assurance that these or any efforts will be successful. However, management believes that these measures will enable the Company to have adequate funds to support operations for the next twelve months.

Note 4 DISCONTINUED OPERATIONS

Effective September 1, 2005, Omni entered into a settlement agreement with McCoy Financial Services, Inc.("MFS") whereby Omni agreed to sell, transfer, and assign to MFS all of the Company's right, title and interest in and to the transcription services segment net assets for \$10,000. As of September 1, 2005, the assets of the transcription services segment was approximately \$221,000 (primarily property and equipment of approximately \$37,000 and intangible assets of \$184,000) and transcription services segment obligations and liabilities had a carrying value of approximately \$527,000 (primarily accounts payable of approximately \$226,000 and debt of approximately \$205,000). A loss on the disposal of the assets was recognized in the amount of \$6,520 The results of operations from the transcription services segment have been retroactively restated as discontinued operations.

Note 5 COMMON STOCK

On November 4, 2005 the Company announced it has executed a 1 for 4 reverse split of it's Common shares effective November 4, 2005, resulting in 12,912,069 shares issued and outstanding after the reverse split.

Note 6 FINANCING/SENIOR NOTE PAYABLE/DERIVATIVES

On October 26, 2005 the Company entered into a Note Purchase Agreement with Sigma Opportunity Fund, LLC. Under the note purchase agreement, Sigma purchased from Omni a Senior Note due April 26, 2006 for \$400,000. Interest is accrued on the note at 5% per annum or 12% per annum in the case of default. In connection with the purchase the Company issued Warrants to purchase 15,000 pre-split shares of Omni common stock for each \$1,000 principal amount of the note for an aggregate of 6,000,000 pre-split shares (1,500,000 post-split shares) with an exercise price of \$.001 per pre-split share (\$.005 per post split share) with a 7-year life. In connection with the Note Purchase Agreement with Sigma Opportunity Fund, LLC, the Company was to file a Registration Statement within 90 days of the closing or suffer a 2% penalty per month of the note amount or \$8,000 per month. The Company has not filed the Registration Statement that was required by the Note Purchase Agreement as of the date of this Report.

The proceeds from the note have been discounted for the relative fair value of the warrants and the discount. All discounts will be amortized over the life of the notes.

F-9

Omni Medical Holdings, Inc. Notes to Condensed Consolidated Financial Statements December 31, 2005

Note 6 FINANCING/SENIOR NOTE PAYABLE/DERIVATIVES-[continued]

The Company has classified the warrants as derivatives and have recorded them at their fair value. The fair value of the warrants is estimated on the commitment date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 250%, risk-free interest rate of 1.5% and expected life of 7 years.

Note 7 SUBSEQUENT EVENTS

On January 20, 2006 the Company issued Warrants to purchase 250,000

post-split shares of the Company's common stock to West Park Capital, Inc.. The warrants are exercisable at \$.01 per share and have a 5-year life.

F-10

Item 2. Management's Discussion and Analysis

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.

This Form 10-QSB Quarterly Report contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Omni Medical Holdings, Inc. is referred to herein as "we" or "our." The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties. Statements made herein are as of the date of the filing of this Form 10-QSB with the Securities and Exchange Commission and should not be relied upon as of any subsequent date. Except as may otherwise be required by applicable law, we do not undertake, and specifically disclaim, any obligation to update any forward-looking statements contained in this Form 10-QSB to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

OVERVIEW:

Omni Medical Holdings (ONMH:OTCBB)provides a turn key back office suite of products and services to doctors, clinics and hospitals throughout the country. Omni continues to grow through its acquisition strategy and unique combination of product offerings.

Omni Medical has positioned itself to offer a complete back office solution of products and services for all medical practitioners.

Omni's DataFuzion subsidiary provides a complete line of integrated backoffice products including GE Centricity and Misys practice management and electronic medical records solutions, and a proprietary web based decision support reporting tools for physicians and hospitals (InfoBridgeTM). Our ASP hosted products are designed to maximize practice performance by identifying revenue enhancement and cost savings opportunities, while eliminating the up front costs and ongoing expense of owning, upgrading, staffing and maintaining multiple in-house operations and reporting systems.

When practitioners provide patient care, those actions must be documented, usually by electronic dictation. Government and insurance regulations are such that these important medical records, which affect patient health, must be in readable form. Through our transcription division, this service can be delivered to any practitioner in the world through our proprietary digital web based system. All of our services are performed in the United States.

Medical billing and collections are the lifeblood of any healthcare facility, with accurate and timely collections insuring an effective practice and high standard of care. The billing process is automated through either of Omni's Centricity or Misys based hubs. Our nearly 20 years of experience extends to most medical areas, especially anesthesiology.

Omni's complete back office solution gives:

- * New revenue opportunities to our customers;
- * More streamlined workflow;
- * Executive managers the ability to use disease management benchmarking data, increasing revenue and providing better patient outcomes;
- * Elimination of costly data errors;
- * Ability to integrate hardware and software with other systems; and
- * "Drill down" from multiple servers, and provides greater analytical solutions.

The opportunities in the healthcare services market are enormous and the next 10 years will bring dramatic changes in how healthcare practitioners manage and operate their practices. Omni Medical Holdings, along with its DataFuzion subsidiary, is currently positioned to take advantage of those opportunities now.

RESULTS OF OPERATIONS

Three months ended December 31, 2005.

During the quarterly period ended December 31, 2005, we recorded revenue from continuing operations of \$1,251,743, a substantial increase from revenue from continuing operations of \$238,518 in the quarter ended December 31, 2004.

Cost of sales from continuing operations totaled \$740,567, versus \$169,180 in the third fiscal quarter of 2005.

During the third fiscal quarter of 2005, we recorded general and administrative expenses of \$1,114,906. These expenses totaled \$178,375 in the year-ago period.

Interest expense was \$281,691 and \$10,461 for the three-month period ended December 31, 2005, and December 31, 2004, respectively.

For the three-month period ended December 31, 2005, we incurred a loss of 780,155, as compared to a loss of 249,402 for the three-month period ended December 31, 2004.

Revenue increased 425% during the three months ended December 31, 2005, compared to the three month period ended December 31, 2004, due to the acquisitions of DataFuzion, Stat Anesthesia and Plum Creek Outpatient. Cost of sales increased 338% and general expenses increased 525% versus the prior year due to higher operating costs associated with DataFuzion and Stat Anesthesia. This included a 363% increase in depreciation expense and a 26 fold increase in interest expense over the previous year. Net loss increased 212% for the previously stated reason. We expect continued high levels of depreciation as DataFuzion takes a conservative accounting approach to its equipment and intangible assets. Interest expense will continue to remain high until such time as the convertible bondholders exchange their debt for equity.

Nine months ended December 31, 2005.

During the nine months ended December 31, 2005, we recorded revenue from continuing operations of \$4,233,046, an increase from revenue from continuing operations of \$722,093 in the nine months ended December 31, 2004.

Cost of sales from continuing operations totaled 2,285,136, versus 431,291 in the nine months ended of 2004.

During the nine months ended December 2005, we recorded general and administrative expenses of \$3,156,581. These expenses totaled \$554,622 in the year-ago nine month period.

Interest expense was \$571,982 and \$28,118 for the nine-month period ended December 31, 2005, and December 31, 2004, respectively.

For the nine-month period ended December 31, 2005, we incurred a loss of \$1,725,339, as compared to a loss of \$520,149 for the nine-month period ended December 31, 2004.

CAPITAL RESOURCE REQUIREMENTS

LIQUIDITY

As of December 31, 2005, Omni's working capital deficit was 4,345,158. Our cash and cash equivalents at December 31, 2005, was 0, and we had a bank overdraft of 10,128.

We currently lease office space under an operating lease for \$6,000 per month, which terminates July 31, 2006.

Effective March 1, 2005, Omni entered into an Employment Agreement with Arthur D. Lyons, its chief executive officer and Douglas Davis, President through March 1, 2010. The agreement provides compensation at an annual base salary of \$180,000, a \$1,000 a month auto allowance, fully paid health insurance and a bonus of 1% of gross revenue, paid quarterly to each.

During December 2003, Omni entered into a Loan Agreement and Security Agreement with Presidential Financial Corporation allowing Omni to borrow up to 80% against certain of its accounts receivable or \$300,000, whichever is less. The loan is secured by accounts receivable and other tangible assets of Omni and accrues interest at prime plus 2%. As of December 31, 2005, approximately \$45,000 was owed on the line of credit.

During August 2005, Omni entered into a Loan Agreement and Security Agreement with Alamo Capital Corporation allowing Omni to borrow 80% against the value of certain specified accounts receivable up to \$500,000. The loan is secured by certain accounts receivable and accrues interest at prime plus 2%. As of December 31, 2005, approximately \$72,000 was owed on this line of credit.

On October 26, 2005, the Company entered into a Note Purchase Agreement with Sigma Opportunity Fund, LLC. Under the note purchase agreement, Sigma purchased from Omni a Senior Note due April 26, 2006, for \$400,000. Interest is accrued on the note at 5% per annum or 12% per annum in the case of default. In connection with the purchase, the Company issued warrants to purchase 15,000 pre-split shares of Omni common stock for each \$1,000 principal amount of the note for an aggregate of 6,000,000 pre-split shares (1,500,000 post-split shares) with an exercise price of \$0.001 per pre-split share (\$0.005 per post split share) with a 7-year life.

The proceeds from the note have been discounted for the relative fair value of the warrants and the discount. All discounts will be amortized over the life of the notes.

The Company has classified the warrants as derivatives and have recorded them at their fair value. The fair value of the warrants is estimated on the commitment date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 250%, risk-free interest rate of 1.5% and expected life of 7 years.

On November 4, 2005, the Company announced it has executed a 1 for 4 reverse

split of its outstanding common shares, effective November 4, 2005.

Item 3. Controls and Procedures.

As of the end of the period covered by this Quarterly Report, we carried out an evaluation, under the supervision and with the participation of our President and Treasurer, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our President and Treasurer concluded that our disclosure controls and procedures are effectively designed to ensure that information required to be disclosed or filed by us is recorded, processed or summarized, within the time periods specified in the rules and regulations of the Securities and Exchange Commission. It should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. In addition, we reviewed our internal controls over financial reporting, and there have been no changes in our internal controls or in other factors in the last fiscal quarter that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

An action has been brought by holders of promissory notes issued by our Company's majority-owned subsidiary, DataFuzion, Inc. for enforcement of the notes and possession of substantially all assets of DataFuzion which are alleged to secure payment of the notes. Plaintiffs filed a motion for possession of the assets, which was denied by the court. DataFuzion does not dispute the execution or delivery of the notes and has recorded the notes in these financial statements. In addition, DataFuzion has some claims against some of the Plaintiffs which may give rise to offsets or counterclaims against some (but in all likelihood, not all) of the Plaintiffs. Those claims have not yet been pled or fully factually explored. The current status of this matter is that the Plaintiffs have filed a Motion for Summary Judgement, seeking judgment for the notes balances (without enforcement of their claimed security interest). DataFuzion has sought and obtained an extension of time to respond to this Motion, and has initiated settlement discussions with Plaintiffs. Those settlement negotiations are ongoing.

Three former employees of DataFuzion have also brought an action against the Company seeking back pay in total of approximately \$60,000. DataFuzion disputes the claims but has offered settlement of approximately \$12,000, which has been rejected. Discussions are ongoing.

Two shareholders of DataFuzion have brought an action against DataFuzion for royalties due them related to new sales of DataFuzion's "Infobridge" software. DataFuzion disputes the amounts owed and has entered into settlement negotiations with the shareholders.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On October 26, 2005 the Company entered into a Note Purchase Agreement with Sigma Opportunity Fund, LLC. Under the note purchase agreement, Sigma purchased from Omni a Senior Note due April 26, 2006, for \$400,000. Interest is accrued on the note at 5% per annum or 12% per annum in the case of default. In connection with the purchase, the Company issued warrants to purchase 15,000 pre-split shares of Omni common stock for each \$1,000

principal amount of the note for an aggregate of 6,000,000 pre-split shares(1,500,000 post-split shares) with an exercise price of \$0.001 per pre-split share (\$0.005 per post split share) with a 7-year life.

On January 20, 2006 the Company issued warrants to purchase 250,000 postsplit shares of the Company's common stock to West Park Capital, Inc. The warrants are exercisable at \$0.01 per share and have a 5-year life.

See Part II, Item 5, below, regarding the Company's one for four reverse split that was effected on November 4, 2005.

We issued these securities to persons who were "accredited investors," and each of whom had prior access to all material information about us. We believe that the offer and sale of these securities was exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Sections 4(2) and 4(6) thereof, and Rule 506 of Regulation D of the Securities and Exchange Commission.

Item 3. Defaults Upon Senior Securities.

None; not applicable.

Item 4. Submission of Matters to a Vote of Security Holders.

None; not applicable.

Item 5. Other Information.

On November 4, 2005, the Company announced it has executed a 1 for 4 reverse split of its outstanding common shares, effective November 4, 2005.

In connection with the Note Purchase Agreement with Sigma Opportunity Fund, LLC, the Company was to file a Registration Statement within 90 days of the closing or suffer a 2% penalty per month of the note amount or \$8,000 per month. The Company has not filed the Registration Statement that was required by the Note Purchase Agreement as of the date of this Report. See the 8-K Current Report dated October 26, 2005 and filed with the Securities and Exchange Commission on November 4, 2005.

Item 6. Exhibits.

(a) Exhibits.

31.1 302 Certification of Douglas Davis.

31.2 302 Certification of Arthur Lyons.

32 906 Certification.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

OMNI MEDICAL HOLDINGS, INC.

Date: 2/13/06

Date: 2/13/06

By: /s/ Arthur D. Lyons

Arthur D. Lyons, CEO, Secretary and Chairman of the Board

By: /s/ Douglas Davis

Douglas Davis, President, Treasurer and Director